We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Russia’s Sputnik V COVID-19 Vaccine Begins Global Phase 3 Trials

By HospiMedica International staff writers
Posted on 19 Aug 2020
Russia’s Sputnik V, the world’s first registered vaccine against COVID-19, has begun Phase III clinical trials.

Similar to the approach adopted for the AstraZeneca-Oxford COVID-19 vaccine, the Sputnik-V vaccine also uses the common cold-causing adenovirus that has been modified to carry genes for the “spike” protein that coats the coronavirus, in order to prime the body to recognize if a real COVID-19 infection strikes. More...
The vaccine, developed jointly by the Gamaleya Research Institute and the Russian Defense Ministry, requires an initial injection and a booster shot 21 days later to confer one- to two-year immunity.

According to details provided on a new website launched by the Russia Direct Investment Fund (RDIF) to share the details of the vaccine with the public and scientists around the world, Sputnik V has gone through all stages of pre-clinical trials with experiments on different types of animals, including two types of primates. The Phase 1 and 2 clinical trials of the vaccine were completed on August 1, 2020. All the volunteers were feeling well, and no unforeseen or unwanted side effects were observed. The vaccine induced strong antibody and cellular immune responses and not a single participant of the current clinical trials was infected with COVID-19 after being administered the vaccine.

The Sputnik V website states that the vaccine’s efficacy was confirmed by high precision tests for antibodies in the blood serum of volunteers (including an analysis for antibodies that neutralize the coronavirus), as well as the ability of the immune cells of the volunteers to activate in response to the spike S protein of the coronavirus, which indicates the formation of both antibody and cellular immune vaccine response. Sputnik V’s Phase 3 clinical trial involving more than 2,000 people has now begun in Russia, and a number of Middle Eastern (UAE and Saudi Arabia), and Latin American countries (Brazil and Mexico).


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Mammography System (Analog)
MAM VENUS
New
High Pressure Balloon Catheter
UroMax Ultra
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.